AEMD — Aethlon Medical, Inc.

Aethlon Medical (AEMD) Q4 2026 Earnings Call Summary

1. Key Financial Results and Metrics:

• Cash Position: As of March 31, 2026, Aethlon Medical reported approximately $5 million in cash and cash equivalents. Post fiscal year-end, the company raised an additional $1.85 million through an at-the-market program.
• Operating Expenses: Consolidated operating expenses decreased by 21.9% year-over-year to approximately $7.3 million, down from $9.3 million in FY 2025. This reduction was attributed to lower payroll, general administrative, and professional fees.
• Net Loss: The net loss attributable to common stockholders was $7.2 million for FY 2026, a significant improvement from a net loss of $13.4 million in FY 2025.

2. Strategic Updates and Business Highlights:

• Clinical Trials: Enrollment for cohort 2 of the Australian oncology trial has been completed, with no safety concerns reported by the independent data safety monitoring board. The company is advancing to cohort 3, where initial treatments have begun.
• Research Initiatives: Aethlon is expanding its Hemopurifier platform applications into preclinical research for diseases like rheumatoid arthritis and chronic kidney disease, focusing on the removal of extracellular vesicles (EVs).
• Ebola Protocol: The compassionate use protocol for Ebola remains open, allowing treatment for up to 20 patients at 10 institutions in the U.S.

3. Forward Guidance and Outlook:

• Aethlon plans to continue advancing its Hemopurifier platform while maintaining disciplined cost control. The company is focused on clinical development, platform expansion, and intellectual property growth.
• The next earnings call is scheduled for August 2026, coinciding with the filing of the quarterly report for Q1 FY 2027.

4. Bad News, Challenges, or Points of Concern:

• Clinical Trial Limitations: The small size of the ongoing clinical trials limits the ability to draw definitive conclusions regarding clinical efficacy, as the primary endpoints focus on safety rather than clinical outcomes.
• Screening Failures: Some patients have been screened out of the trial due to not meeting inclusion/exclusion criteria, which is a common challenge in clinical studies.

5. Notable Q&A Insights:

• The compassionate use protocol for Ebola is distinct from previous treatments for other diseases, with a specific focus on Ebola patients.
• Aethlon is conducting preclinical activities in a cost-effective manner, aiming to build a database for future publications and presentations.
• Positive preliminary findings were discussed regarding the Hemopurifier's effects on EVs and T cells, with potential implications for enhancing therapies like KEYTRUDA and Opdivo.
• The management expressed optimism about ongoing engagement from clinical trial sites and the interest in participant enrollment.

Overall, Aethlon Medical is making strides in its clinical and research initiatives while effectively managing costs, though it faces challenges related to the limitations of its clinical trials and patient enrollment criteria.